46 results about "Beta-boswellic acid" patented technology

A composition for treating inflammation and pain in mammals, particularly humans. Effective amounts of a boswellic acid, a curcuminoid, a gingerol, a capsaicinoid, a bioflavonoid, and a vitamin C source, in various combinations, all preferably from a botanical source, are blended to form a dose for oral administration. Administration of the dose provides relief from pain and inflammation of connective tissue. The dose may be administered as a tablet, a liquid, or a powder.

The invention describes a nutraceutical composition and method for preventing / treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.

A composition suitable for use on the skin or hair comprising: a) at least one extract of a Boswellia plant or at least one boswellic acid; and b) a carrier selected from the group consisting of branched fatty alcohols containing 8 to 32 carbon atoms, branched fatty acids containing 8 to 32 carbon atoms, unsaturated fatty alcohols containing 12 to 24 carbon atoms, unsaturated fatty acids containing 12 to 24 carbon atoms and derivatives of said branched fatty alcohols, said branched fatty acids, said unsaturated fatty alcohols and said unsaturated fatty acids, or mixtures thereof.

A lip balm product having a synthetic ceramide, an anti-irritant compound, sodium hyaluronate, cosmetic wax, boswellic acids and / or esters and / or salts thereof, extract of the Portuluca pilosa plant, matrikin-mimetic peptide, dehydrated microspheres of marine collagen and glycosaminoglycans, and mica along with optional lip balm formulation acceptable carriers and / or solvents. Where desired, the lip balm may further contain medicinal agents suitable for the treatment of various conditions of the lip.

A dietary supplement composition for enhancement of the insulin sensitivity is provided, which includes thiamin, chromium, alpha-lipoic acid, L-carnosine, and vanadium. The supplement composition further includes cinnamon bark and banana leaf extract (corosolic acid) for an extra strength formula. Alternatively, the supplement composition includes a herbal blend which includes boswellic acid, gymnema sylvestre leaf extract, and bitter melon extract. Further provided is a method of using the supplement composition for enhancing an individual's insulin sensitivity.

The present invention relates to formulations comprising combinations of analgesic / anti-inflammatory, immunomodulating and cartilage-reconstructing agents in particular comprising saligenig, boswellic acid, procyanidins, N-acety-glucosamine and either glucoronic acid or glucoronolactone, for the treatment of rheumatoid arthritis and, more generally, of arthritis conditions.

The present invention relates to pharmaceutical compositions comprising ester(s) of capsaicin and at least one other agent selected from salicylates, menthol, boswellic acids, DMSO, methyl sulfonylmethane, NSAIDs, corticosteroids, emu oil, opioid agonists and antagonists, NMDA antagonists, tramadol, hyaluronic acid, α2δ ligands, santalol, santalyl acetate, amyris alcohol, amyris acetate, aloe vera gel and aloe vera juice, for improved therapeutic properties. Further, the present invention relates to pharmaceutical compositions comprising high concentrations of ester(s) of capsaicin. Further, the present invention relates to a method of relieving pain due to various diseases in subjects by administering the pharmaceutical compositions of the invention. Further, the present invention relates to methods of relieving fever blisters due to cold sores in subjects by administering the pharmaceutical compositions comprising an ester of capsaicin and one other agent selected from santalol, santalyl acetate, amyris alcohol and amyris acetate.

Treatment for Cancer Using A Preparation containing a combination of one or more Natural or Synthetic or a Combination of Natural and Synthetic Boswellic Acids and one or more Natural or Synthetic or a Combination of Natural and Synthetic Cytokinins such as Kinetin, Kinetin Riboside and other Cytokinins and (the Preparation) could also contain one or more Natural or Synthetic or a Combination of Natural and Synthetic plant growth hormones such as Auxins in any percentage Ratio and could Optionally include Pharmaceutically Suitable Radioactive Agent (Radio Therapy) in any percentage ratio as a “Stand Alone” Treatment for Cancer or to Be used in Conjunction with other Pharmaceutically Suitable Therapy and Treatment(s) in any percentage ratio as a Treatment for Treating Cancer.

Disclosed are sustained-release medicaments / drug compositions / formulations / therapeutics for the management of pain and inflammation associated disorders in general, more particularly arthritic inflammation. The sustained-release compositions comprise effective amounts of glucosamine, curcuminoids, boswellic acids and piperine.

A method of treatment of lymphoproliferative and autoimmune disorders with a new composition of four boswellic acids including β-boswellic acid, 3-O-acetyl-β-boswellic acid, 11-keto-β-boswellic acid, and 3-O-acetyl-11-keto-β-boswellic acid. Boswellic acids of invention have been obtained in a novel industrial process from the gum resin of Boswellia serrata tree, providing standardized composition which inhibits DNA, RNA and protein synthesis of the target cell without cytotoxic effects. The composition of invention provides advantage of irreversible cytostatic therapy, equivalent to biological effects of a cytotoxic therapy without killing body cells.

Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of Boswellia serrata. More particularly, these herbal compositions comprise an effective amount of an enriched Boswellia extract containing from 10% to 99% by weight of 3-0-acetyl-11-keto-β-boswellic acid; and an effective amount of a second extract selected from the group consisting of an extract of Aegle marmelos, an extract of Zingiber officinale, an extract of Garcinia mangostana, and mixtures thereof. These may be used in dietary supplements or pharmaceutical formulations for controlling diseases associated with or related to inflammation. These diseases in particular include respiratory disorders such as asthma, allergic rhinitis, hay fever, type-1 hypersensitivity and mild allergies. The compositions can also be useful for skin care.

New salts or ion pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or 11-keto-β-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also be used in cosmetic or pharmaceutical composition for external treatment of body parts or organs to treat inflammatory diseases or cancer.

The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic acids. These compounds may be used for the treatment of cancer, alone or in combination with pharmaceutically acceptable or other carriers, displaying cytotoxicity and anti-cancer activity for colon, prostrate, liver, breast, central nervous system (CNS), leukemia and malignancy of other tissues, including ascites and solid tumors. The cancer cell death is mediated by induction of apoptosis and inhibition of cell proliferation at specific doses.

Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-ss-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and antioxidant activities. Also disclosed are novel compositions comprising enriched 3-0-acetyl-ll-keto-ss- boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of- COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methylsulphonylmethane, bromelain, serratiopeptidase,quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.

The present disclosure is directed to compositions and methods for formulating a pharmaceutical dosage form by forming a composition comprising acetyl-11-keto-β-boswellic acid, diindolylmethane, or curcumin with one or more pharmaceutically acceptable excipients for enhanced solubility to increase bioavailability and improve therapeutic efficacy. The composition can be processed by thermo-kinetic compounding along with conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide faction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises use of polysaccharide fraction individually or in combination with boswellic acid fraction for inhibition of PGE2.

The present invention is the application of acetyl boswellic acid (BC-4) extracted from Boswellia carterii Birdw as antitumor medicine, a secondary application. It is found that BC-4 has the functions of resisting the proliferation of tumor cell, inducing malignant tumor cell to death, inhibiting the proliferation of human umbilical vein endothelial cell, inhibiting animal's grafted tumor, inhibiting metastasis of malignant tumor, etc. Both in vivo and vitro tests show that BC-4 has very low toxicity and is one excellent antitumor medicine and tumor metastasis inhibitor.

The invention relates to six new compounds for treating psoriasis, a preparation method and an application thereof. The six new compounds belong to a series of derivatives from a mother compound: acetyl-11-keto-[beta]-boswellic acid (AKBA) through modification of a hydrolysis reaction and an esterification reaction. Compared with the mother compound AKBA before chemical modification, the six compound, of which the structure are represented as the formulas (II-VII), can inhibit division and cell proliferation of keratinocyte in in-vitro experiments and can treat the psoriasis on mice more effectively in a live animal test. The new compounds can be used for preparing the medicine for treating the psoriasis.

The invention discloses a method for extracting a mass of 11-carbonyl-beta-acetylboswellic acid (AKBA) from frankincense and application thereof in resisting glioma and breast cancer. It is found that11-carbonyl-beta-acetylboswellic acid has a significant inhibitory effect on the growth of human glioma cells A172 and human breast cancer cell line MDA-MB-231, and can be used as a medicine for treatment of glioma and breast cancer.

Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of Boswellia serrata. More particularly, these herbal compositions comprise an effective amount of an enriched Boswellia extract containing from 10% to 99% by weight of 3-0-acetyl-11-keto-β-boswellic acid; and an effective amount of a second extract selected from the group consisting of an extract of Aegle marmelos, an extract of Zingiber officinale, an extract of Garcinia mangostana, and mixtures thereof. These may be used in dietary supplements or pharmaceutical formulations for controlling diseases associated with or related to inflammation. These diseases in particular include respiratory disorders such as asthma, allergic rhinitis, hay fever, type-1 hypersensitivity and mild allergies. The compositions can also be useful for skin care.

A medical composition and devices made from the composition for the delivery of extracts obtained from Boswellia genus, similar compounds synthetically derived, and in particular derivatives of triterpenes is disclosed. The medical device may be implantable, or alternatively a device which contacts the interior of a mammalian body. The medical device may be comprised, of or present an absorbable component containing Boswellia derivatives, or an eluting component. When administered into a particular body site, the Boswellia component may be released substantially and immediately, released slowly, or not released, into the body and residing actively on the medical device surface.

Treatment for Cancer Using A Preparation containing a combination of one or more Natural or Synthetic or a Combination of Natural and Synthetic Boswellic Acids and one or more Natural or Synthetic or a Combination of Natural and Synthetic Cytokinins such as Kinetin, Kinetin Riboside and other Cytokinins and (the Preparation) could also contain one or more Natural or Synthetic or a Combination of Natural and Synthetic plant growth hormones such as Auxins in any percentage ratio for Treating Cancer.The said Components of the said Preperation works by Inducing Apoptosis of the Cancerous cells, by “executing” them by Inducing Caspases-8 and other mechanisms.With the Said Preparation being administered in a Mode or dosage that the Doctor and or Healthcare Practitioner would Prescribe

The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-O-acetyl-1 1-keto-ss- boswellic acid (AKBA) derived from Boswellia serrata and Boswellia serrata non- acidic resin extract (BNRE). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, endothelial dysfunction and the like. The invention further discloses the amelioration of pro-inflammatory biomarker proteins or molecules, whose expression / production is altered during inflammatory diseases.

The invention relates to a treating agent for removing drug residues in wastewater of an amoxicillin production workshop. The treating agent is compounded from components as follows: 2, 6-dimethyl-2,6-octadiene-8-ol, actein, methyl 2-aminobenzoate, ferrous gluconate, psoralen, 4-methyl-1-(1-methyl ethyl)-3-cyclohexene-1-ol, 2,4-dimethylthiazole, salicin, schisandrin, polyoxyethylene lauryl ether, cyclopentadecanolide, imperatorin, polyacrylamide, acetyl-11-carbonyl-beta-boswellic acid and isolicoflavone. The treating agent has high complexing capability with a target substance, and the removal rate can reach 99.9%.

The invention relates to six new compounds for treating psoriasis, a preparation method and an application thereof. The six new compounds belong to a series of derivatives from a mother compound: acetyl-11-keto-[beta]-boswellic acid (AKBA) through modification of a hydrolysis reaction and an esterification reaction. Compared with the mother compound AKBA before chemical modification, the six compound, of which the structure are represented as the formulas (II-VII), can inhibit division and cell proliferation of keratinocyte in in-vitro experiments and can treat the psoriasis on mice more effectively in a live animal test. The new compounds can be used for preparing the medicine for treating the psoriasis.

The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide faction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises use of polysaccharide fraction individually or in combination with boswellic acid fraction for inhibition of PGE2.

The invention provides an application of 3-acetyl-alpha,beta-boswellic acid and a medicine to treat pancreatitis, and relates to the technical field of medicines. The invention confirms through experiments that 3-acetyl-alpha,beta-boswellic acid inhibits inflammation, and treats pancreatitis. Through application of 3-acetyl-alpha,beta-boswellic acid in preparation of a medicine to prevent and / or treat pancreatitis, the invention may effectively inhibit pancreas inflammation, thereby greatly improving the treatment effect of pancreatitis, so as to provide basis for clinical experiments, and provide a new approach for the development of new medicines. The active ingredient of the medicine to prevent and / or treat pancreatitis provided in the invention is 3-acetyl-alpha,beta-boswellic acid, and therefore may effectively inhibit the pancreas inflammation, so as to play a significant role in the prevention and / or treatment of pancreatitis, and the medicine is safe and non-toxic, and has small side effects.

The present invention relates to a composition comprising: astaxanthin, piperine, boswellic acids, coenzyme Q10, curcuminoids, lutein, zeaxanthin, saffron, copper and, optionally, resveratrol, bromelain, zinc, salicin and further antioxidants from natural sources. The present invention further relates to said composition for use in treating retinal diseases which are ischemic and / or degenerative in nature.